Thought-provoking interviews with industry experts on topics critical to the diagnosis, treatment, and prevention of progressive eye health.
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.
How to diagnose geographic atrophy earlier
Carl Danzig, MD, points out that the sooner patients can be diagnosed, the sooner ophthalmologists can treat them and preserve their vision.
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Tom Ruggia, President and CEO of Samsara Vision, provides updates on the lead asset for late-state age-related macular degeneration: Smaller-incision, new generation, implantable miniature telescope (SING IMT).
Understanding fluid dynamics in wet macular degeneration
At AAO 2022, Justis Ehlers, MD, presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Tunde Peto, MD, PhD, shares some ophthalmic initiatives she's excited about in light of EURETINA 2022.
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
Tunde Peto, MD, PhD, discussed two of her presentations at EURETINA 2022: "UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases" and "Retinal phenotyping of different variants of Alzheimer’s disease using ultra-widefield imaging."
EURETINA 2022: Leadership discusses what to expect, outlines Women in Retina program
Dara Conlon, Executive Vice President of EURETINA, and Prof. Anat Loewenstein, General Secretary of EURETINA, discuss some key features of this year's Congress.
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
Nancy Lurker, CEO of EyePoint Pharmaceuticals, shares the 12-month safety data from the DAVIO trial, investigating EYP-1901 for the treatment of wet age-related macular degeneration (AMD) and nonproliferative diabetic retinopathy.
Phase 4 Paladin finds fluocinolone to be safe, effective in patients with diabetic macular edema
Victor Gonzalez, MD, shares updates from the Phase 4 Paladin study regarding the safety and efficacy of fluocinolone in diabetic macular edema.
Foundation Fighting Blindness: Building a toolbox of therapies for dry AMD, inherited retinal diseases
Claire Gelfman, PhD, Chief Scientific Officer of Foundation Fighting Blindness, supplies a brief overview of the foundation's aims and updates on retinal disease research.
Faricimab for DME: Personalized treatment interval dosing maintains visual acuity, reduces treatment burden
At ASRS 2022, John Kitchens, MD, presented, “Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab."
Diabetic retinopathy eye drop: Phase 1B clinical results show promise
Kerrie Brady, CEO of OcuTerra Therapeutics, shares an update on their eye drop-based integrin inhibitor, which is intended to be a novel therapy for diabetic retinopathy.
Quicker time to surgery affects VA outcomes in macula-on rhegmatogenous retinal detachments
At ASRS 2022, Sunir Garg, MD, FACS, discussed his talk entitled, “Impact of Delay in Repair of Rhegmatogenous Retinal Detachment: Real-World Outcomes from the IRIS Registry.”
Giant retinal tear-related detachments: Pediatric eyes repair better after vitrectomy with scleral buckling; adults only need vitrectomy
At ASRS 2022, Sally Ong, MD, presented a talk entitled, “Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicenter Study.” Here she shares the biggest takeaways.
KALAHARI study: Phase 2 early results indicate alternative treatment pathway for patients with DME is effective, durable
Rahul Khurana, MD, discusses his 2022 ASRS talk, “Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor in Patients With DME Who Respond Suboptimally to Anti-VEGF Treatment (Month 6 Results of Part A of the KALAHARI Study),” which he presented in New York City, New York.
Elevated albumin to creatinine ratio associated with central subfield thickness fluctuations in patients with DME
At ASRS in New York, Matthew Starr, MD, presented, “Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases.”
RGX-314 demonstrates DRSS improvements in patients with DME, NPDR
At ASRS in New York City, Charles Wykoff, MD, presented a talk entitled, “Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study.” The trial demonstrated large improvements for patients with diabetic macular edema (DME) and non-proliferative diabetic retinopathy (NPDR), with notable improvements according to the Diabetic Retinopathy Severity Scale (DRSS).
DAVIO trial: 12-month results show favorable safety profile, reduced treatment burden in patients with nAMD
At ASRS 2022 in New York City, New York, Rishi Singh, MD, is presenting, “12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial.” The Phase 1 trial showed a reduction in treatment burden over 12 months as well as a favorable safety profile.
PEACHTREE post hoc analysis: Significant reduction of macular edema, low rate of rescue in patients with chronic uveitis
Christopher Henry, MD, presented a talk entitled, “Efficacy of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in the Treatment of Macular Edema in Patients With Chronic Uveitis,” at ASRS 2022 in New York City, New York.
DME: Faricimab remains durable, effective in 2-year results of YOSEMITE and RHINE trials
At ASRS in New York City, New York, David Eichenbaum, MD, presented “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-year Results on the Phase 3 YOSEMITE and RHINE Trials.”
Delving into the 24-week results for UBX1325 for the treatment of chronic DME, wet AMD
At ASRS 2022, Raj K. Maturi, MD, presented a talk entitled, “UBX1325, A Novel Senolytic Therapy for Treatment- Experienced Patients With Chronic DME or Wet AMD: 24-Week Results of a Phase 1 Study.”
The relationship between outer retinal integrity, subretinal fluid may affect treatment outcomes
At ASRS in New York City, New York, Justis Ehlers, MD, presented a talk entitled, “Higher Order OCT Feature Assessments of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity.” Here he discusses the findings.
Miniature telescope in dry AMD: Surgical implantation improves vision for patients with late-stage AMD
Albert J. Augustin, MD, presented a talk entitled, “First Results of the Miniature Telescope in Dry AMD” in Fort Lauderdale, Florida. The Galilean telescope device offers visual improvements for patients with late-stage AMD.
AAVIATE: Gene therapy via suprachoroidal drug delivery may lower treatment burden for patients with AMD
Rahul Khurana, MD, offers updates and details about the Aaviate study, which is investigating a possibly once-and-done gene therapy option for macular degeneration via suprachoroidal drug delivery.
Evaluating effect of central subfield thickness, volatility on visual acuity in clinical trials for nAMD
Justis P. Ehlers, MD, dissects the revelations from the data in the Phase 3 Hawk clinical trial regarding the impact of central subfield thickness, volatility and the overall impact on visual acuity.
Copernicus and Galileo trials: Effect of time since diagnosis on BCVA outcomes in CRVO
Dilsher Dhoot, MD, discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.
Phase 3 Archway end-of-trial results: Port Delivery System is noninferior to monthly ranibizumab
Aleksandra Rachitskaya, MD, discussed the Phase 3 Archway end-of-trial results for the investigation of the Port Delivery System with ranibizumab in neovascular AMD.
Morphologic features of vitreous cortex hyalocyte captured with OCT
Richard Rosen, MD, shares insights on how imaging can capture hyalocytes and their movement without the use of dyes.
Expanding the therapeutic arsenal for noninfectious uveitis, uveitic macular edema
Steven Yeh, MD, provides a brief overview of available therapies for noninfectious uveitis and uveitis macular edema.
2 Clarke Drive Cranbury, NJ 08512